Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC ZOVIRAX PATIENT ASSISTANCE PROGRAM

This article was originally published in The Tan Sheet

Executive Summary

OTC ZOVIRAX PATIENT ASSISTANCE PROGRAM is being considered by Burroughs Wellcome in preparation for the Rx-to-OTC switch of oral acyclovir for the management of recurrent genital herpes, the company told FDA in a recent letter. "Although over-the-counter status will make Zovirax more widely available," Burroughs Wellcome said it recognizes that an Rx-to-OTC switch "may change the ways in which people with limited financial means currently obtain the medication."

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS082662

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel